Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications.

A new bifunctional ligand 3p-C-DEPA was synthesized and evaluated for use in targeted α-radioimmunotherapy. 3p-C-DEPA was efficiently prepared via regiospecific ring opening of an aziridinium ion and conjugated with trastuzumab. The 3p-C-DEPA-trastuzumab conjugate was extremely rapid in binding (205/6)Bi, and the corresponding (205/6)Bi-3p-C-DEPA-trastuzumab complex was stable in human serum. Biodistribution studies were performed to evaluate in vivo stability and tumor targeting of (205/6)Bi-3p-C-DEPA-trastuzumab conjugate in tumor bearing athymic mice. (205/6)Bi-3p-C-DEPA-trastuzumab conjugate displayed excellent in vivo stability and targeting as evidenced by low organ uptake and high tumor uptake. The results of the in vitro and in vivo studies indicate that 3p-C-DEPA is a promising chelator for radioimmunotherapy of (212)Bi and (213)Bi.

[1]  Thien Le,et al.  A highly effective bifunctional ligand for radioimmunotherapy applications. , 2011, Chemical communications.

[2]  M. Brechbiel,et al.  Synthesis and biological evaluation of a novel decadentate ligand DEPA. , 2008, Bioorganic & medicinal chemistry letters.

[3]  R. Senekowitsch-Schmidtke,et al.  Preclinical Evaluation of the α-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors , 2008, Clinical Cancer Research.

[4]  S. Kneifel,et al.  Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P , 2006, Clinical Cancer Research.

[5]  M. Brechbiel,et al.  Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. , 2005, Cancer biotherapy & radiopharmaceuticals.

[6]  Yong Li,et al.  Intralesional targeted alpha therapy for metastatic melanoma , 2005, Cancer biology & therapy.

[7]  T. Quinn,et al.  Melanoma Therapy via Peptide-Targeted α-Radiation , 2005, Clinical Cancer Research.

[8]  M. Brechbiel,et al.  Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease , 2004, Clinical Cancer Research.

[9]  M. Brechbiel,et al.  Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. , 2004, Nuclear medicine and biology.

[10]  D. Scheinberg,et al.  Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids , 2004, Clinical Cancer Research.

[11]  M. Brechbiel,et al.  Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.

[12]  L. Chappell,et al.  Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins. , 2003, Nuclear medicine and biology.

[13]  D. Scheinberg,et al.  Design and synthesis of 225Ac radioimmunopharmaceuticals. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[14]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[15]  M. Brechbiel,et al.  The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. , 2001, Chemical reviews.

[16]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[17]  R. Dillman,et al.  Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. , 2000, Seminars in oncology.

[18]  R. Meredith,et al.  Clinical radioimmunotherapy. , 2000, Seminars in radiation oncology.

[19]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  O. Gansow,et al.  The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. , 1996, International journal of radiation oncology, biology, physics.

[21]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[22]  M. Brechbiel,et al.  Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter , 1992 .

[23]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .

[24]  A. M. Friedman,et al.  An improved generator for the production of 212Pb and 212Bi from 224Ra. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[25]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.